Contact Us
en
TH

Our Story

Inspire IVF Public Company Limited was established on March 16, 2018, by a group of entrepreneurs and medical experts in reproductive medicine. They recognized the potential and growth opportunities in the comprehensive fertility treatment center business in Thailand.

Led by Mr. Chanachai Joonjiraporn, a business expert in financial management and investment, Dr. Puttipong Poomsuwan, a businessman and expert in aesthetic medicine, and Dr. Santha Srisuparp, a specialist in reproductive medicine, Inspire IVF offers comprehensive services ranging from fertility treatment planning to personalized treatment options tailored to each individual. With a dedicated team of experienced professionals, every detail is carefully attended to, utilizing advanced reproductive technologies to increase the success rate of pregnancy for couples.

Under the concept of operating a comprehensive fertility treatment center, Inspire IVF is committed to providing services with an emphasis on international standards.
The company has assembled a team of specialists and invested in modern equipment, tools, and laboratories. It is the first in the fertility treatment center business in Asia to receive both AACI and ISO:9001 certifications. The AACI standard is currently the only global standard that can certify both International Healthcare Standards and ISO & EN simultaneously. Additionally, the company is officially the second in the world to be accredited by Global Healthcare Accreditation (GHA) for the COVID-19 program specifically designed for medical travel, highlighting its commitment to international healthcare quality management systems.

Certified by Temos International Healthcare Accreditation, Germany (Trust, Effective Medicine, Optimized Services) in the "Excellent in International Reproductive Care" program, the clinic also received accreditation from the Diplomatic Council (DC). It is the first clinic in Thailand and Southeast Asia to achieve this recognition, with a strong emphasis on patient safety and delivering the highest quality of care.

Vision

Leaders in Asia's comprehensive fertility care, adhering to global standards, focused on delivering the highest level of patient satisfaction, and committed to inspiring happiness in every family.

Mission

Commitment to Advanced Technology Services
We are a clinic dedicated to providing comprehensive fertility services using advanced technologies, aimed at increasing the success rate for individuals facing fertility challenges.
Focus on Enhancing Workforce Potential
We carefully select highly experienced and knowledgeable personnel while continuously promoting the learning of new medical and technological advancements. We place significant emphasis on developing the capabilities of our medical staff, embryologists, and genetic screening scientists to ensure the highest quality of care.
Emphasis on International Standards
We prioritize maintaining the highest international standards in fertility treatment to ensure the best possible care for our patients.
Commitment to Business Growth and Sustainability
The company is dedicated to fostering growth and sustainability both now and in the future. We strive to provide excellent services and utilize cutting-edge technologies to ensure maximum efficiency while adhering to good governance and social responsibility principles.

Core Values

I
Inspire
N
New Knowledge
S
Simplification
P
Passion
I
Integrity
R
Responsibility
E
Excellent

Milestones

March

Inspire IVF Co., Ltd. was established in 2018 with a registered capital of 65 million THB.

July

The company began operations by leasing space at Ploenchit Center to serve as a clinic offering fertility consultations, including planning and treatment options to help couples achieve their desired pregnancy.

November

Increased registered capital to 90 million THB to purchase equipment and tools for business operations, such as ultrasound machines, sterile IVF cabinets, and microscopes.
March

Participated in The Infertility Conference at YiWu Minimally Invasive Surgery Hospital in the People's Republic of China to present and exchange academic knowledge on infertility treatment.

June

Attended The 35th Annual Conference of the European Society of Human Reproductive and Embryology in Austria to study advanced technologies in infertility treatment.

The global outbreak of COVID-19, including in Thailand, led to travel restrictions. People worldwide were unable to travel internationally, which prevented the company’s foreign clients from accessing its services.
March

Received international accreditation from GHA for the COVID-19 Guidelines for Medical Travel Program, ensuring health tourism standards during the pandemic.

May

Achieved ISO9001 and AACI (American Accreditation Commission International) certifications, which are international quality assurance standards from the United States. AACI helps elevate the quality of service facilities, ensuring client safety, accurate treatment, consultation, medication, and post-treatment care. It also guarantees proper procedures, standard equipment, and the high quality of personnel.
  • The COVID-19 pandemic began to subside, allowing international clients to resume using the company’s services.
  • The company started hiring additional staff and implemented a green ERP system to enhance operational efficiency, preparing for its listing on the Market for Alternative Investment (MAI).
May

Provide services in Preventive and Regenerative Medicine.

June - July

Restructured capital by reducing registered capital from 90 million THB to 75 million THB with a par value of 100 THB per share to offset accumulated losses, then increased registered capital to 105 million THB for working capital.

September

Transitioned to Inspire IVF Public Company Limited and increased registered capital to 155 million THB with a par value of 100 THB per share for working capital.
March

Changed the par value of shares from 100 THB per share to 0.50 THB per share. Increased registered capital from 155 million THB to 220 million THB by issuing 130 million new ordinary shares with a par value of 0.50 THB per share, to be offered to the public.

June

Invested in the EmbryoScope Time-Lapse System for embryo culture

August

Received international certification for Excellent in International Reproductive Care from Temos